Fatty acid-anticancer conjugates and uses thereof

• US 7,235,583 B1
• Filed: 03/09/1999
• Issued: 06/26/2007
• Est. Priority Date: 03/09/1999
• Status: Expired due to Fees

• Current Assignee: Luitpold Pharmaceuticals Incorporated (Daiichi Sankyo Company Limited)
• Original Assignee: Luitpold Pharmaceuticals Incorporated (Daiichi Sankyo Company Limited)
• Inventors: Bradley, Matthews O., Webb, Nigel L., Anthony, Forrest, Fisher, Mark
• Primary Examiner(s): RAHMANI, NILOOFAR
• Application Number:
  US09/265,307
• Time in Patent Office: 3,031 Days
• Field of Search: 514/449, 549/510, 549/511
• US Class Current: 514/449
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

The invention provides conjugates of fatty acids and anticancer agents useful in treating cancer, and compositions and formulations thereof. Methods for using the conjugates also are provided.

Claims

1. A fatty acid-anticancer compound conjugate composition for administration to a subject, comprising at least one fatty acid-anticancer compound conjugate in a container for administration to a subject, wherein the amount of the fatty acid-anticancer compound in the container is at least about 30% on a molar basis greater than the maximum tolerated dose (MTD) in the subject for the unconjugated at least one anticancer compound, wherein the container is a container for intravenous administration.

2. The fatty acid-anticancer compound conjugate composition of claim 1, wherein the amount in the container is at least about 50% greater than the MTD for the unconjugated at least one anticancer compound.

3. The fatty acid-anticancer compound conjugate composition of claim 1, wherein the amount in the container is at least about 100% greater than the MTD for the unconjugated at least one anticancer compound.

4. The fatty acid-anticancer compound conjugate composition of claim 1, wherein the anticancer compound is a taxane.

29. The fatty acid-anticancer compound conjugate composition of claim 1, wherein the amount in the container is at least about 40% greater than the MTD for the unconjugated at least one anticancer compound.

30. The fatty acid-anticancer compound conjugate composition of claim 1, wherein the amount in the container is at least about 75% greater than the MTD for the unconjugated at least one anticancer compound.

31. The fatty acid-anticancer compound conjugate composition of claim 1, wherein the container is a container for intravenous administration.

32. The fatty acid-anticancer compound conjugate composition of claim 4, wherein the taxane is paclitaxel or docetaxel.

33. The fatty acid-anticancer compound conjugate composition of claim 1, wherein the conjugate is not encapsulated in a liposome.

34. The fatty acid-anticancer compound conjugate composition of claim 1, wherein the fatty acid is docosahexaenoic acid.

5. A method for treating a subject having an abnormal mammalian cell proliferative disorder, comprising administering to the subject a fatty acid-anticancer compound conjugate composition in an amount which is at least about 30% on a molar basis greater than the maximum tolerated dose (MTD) in the subject for the unconjugated at least one anticancer compound.

6. The method of claim 5, wherein the amount of the fatty acid-anticancer compound conjugate composition administered is at least about 50% greater than the MTD for the unconjugated at least one anticancer compound.

7. The method of claim 5, wherein the amount of the fatty acid-anticancer compound conjugate composition administered is at least about 100% greater than the MTD for the unconjugated at least one anticancer compound.

8. The method of claim 5, wherein the anticancer compound is a taxane.

35. The method of claim 5, wherein the amount of the fatty acid-anticancer compound conjugate composition administered is at least about 40% greater than the MTD for the unconjugated at least one anticancer compound.

36. The method of claim 5, wherein the amount of the fatty acid-anticancer compound conjugate composition administered is at least about 75% greater than the MTD for the unconjugated at least one anticancer compound.

37. The method of claim 8, wherein the taxane is paclitaxel or docetaxel.

38. The method of claim 5, wherein the conjugate is not encapsulated in a liposome.

39. The method of claim 5, wherein the fatty acid is docosahexaenoic acid.

9. A kit for administration of a fatty acid-anticancer compound conjugate composition to a subject, comprising

a container containing at least one fatty acid-anticancer compound conjugate, and

instructions for administering the at least one fatty acid-anticancer compound conjugate to subject in need of such treatment in an amount which is at least about 30% on a molar basis greater than the maximum tolerated dose (MTD) in the subject for the unconjugated at least one anticancer compound.

40. The kit of claim 9, wherein the amount of the at least one fatty acid-anticancer compound conjugate is at least about 40% greater than the MTD for the unconjugated at least one anticancer compound.

41. The kit of claim 9, wherein the amount of the at least one fatty acid-anticancer compound conjugate is at least about 75% greater than the MTD for the unconjugated at least one anticancer compound.

42. The kit of claim 9, wherein the at least one fatty acid-anticancer compound conjugate is a taxane.

43. The kit of claim 42, wherein the taxane is paclitaxel or docetaxel.

44. The kit of claim 9, wherein the conjugate is not encapsulated in a liposome.

45. The kit of claim 9, wherein the fatty acid is docosohexaenoic acid.

10. An injectable preparation of at least one fatty acid-taxane conjugate composition, comprising greater than about 6 mg/ml of the at least one fatty acid-taxane conjugate composition.

11. The injectable preparation of claim 10, wherein the preparation comprises greater than about 20 mg/ml of the at least one fatty acid-taxane conjugate composition.

12. The injectable preparation of claim 10, wherein the preparation comprises greater than about 80 mg/ml of the at least one fatty acid-taxane conjugate composition.

55. The injectable preparation of claim 10, wherein the preparation comprises greater than about 7 mg/ml of the at least one fatty acid-taxane conjugate composition.

56. The injectable preparation of claim 10, wherein the preparation comprises greater than about 8 mg/ml of the at least one fatty acid-taxane conjugate composition.

57. The injectable preparation of claim 10, wherein the preparation comprises greater than about 10 mg/ml of the at least one fatty acid-taxane conjugate composition.

58. The injectable preparation of claim 10, wherein the preparation comprises greater than about 15 mg/ml of the at least one fatty acid-taxane conjugate composition.

59. The injectable preparation of claim 10, wherein the preparation comprises greater than about 40 mg/ml of the at least one fatty acid-taxane conjugate composition.

60. The injectable preparation of claim 10, wherein the preparation comprises greater than about 60 mg/ml of the at least one fatty acid-taxane conjugate composition.

61. The injectable preparation of claim 10, wherein the preparation comprises greater than about 100 mg/ml of the at least one fatty acid-taxane conjugate composition.

62. The injectable preparation of claim 10, wherein the fatty acid is a C8-C26 unbranched, naturally occurring fatty acid.

63. The injectable preparation of claim 62, wherein the fatty acid is docosohexaenoic acid.

13. An injectable composition of at least one fatty acid-taxane conjugate in a polyoxyethylated castor oil, comprising less than about 0.3 mg/ml of the at least one fatty acid-taxane conjugate.

14. A fatty acid-taxane conjugate composition, comprising greater than about 6 mg/ml of at least one fatty acid-taxane conjugate, and a surfactant.

15. The fatty acid-taxane conjugate composition of claim 14, wherein the amount of the at least one fatty acid-taxane conjugate is greater than about 20 mg/ml.

16. The fatty acid-taxane conjugate composition of claim 14, wherein the amount of the at least one fatty acid-taxane conjugate is greater than about 80 mg/ml.

17. The fatty acid-taxane conjugate composition of claim 14, wherein the surfactant is a polyoxyethylated castor oil.

64. The fatty acid-taxane conjugate composition of claim 14, wherein the amount of the at least one fatty acid-taxane conjugate is greater than about 7 mg/ml.

65. The fatty acid-taxane conjugate composition of claim 14, wherein the amount of the at least one fatty acid-taxane conjugate is greater than about 8 mg/ml.

66. The fatty acid-taxane conjugate composition of claim 14, wherein the amount of the at least one fatty acid-taxane conjugate is greater than about 10 mg/ml.

67. The fatty acid-taxane conjugate composition of claim 14, wherein the amount of the at least one fatty acid-taxane conjugate is greater than about 15 mg/ml.

68. The fatty acid-taxane conjugate composition of claim 14, wherein the amount of the at least one fatty acid-taxane conjugate is greater than about 40 mg/ml.

69. The fatty acid-taxane conjugate composition of claim 14, wherein the amount of the at least one fatty acid-taxane conjugate is greater than about 60 mg/ml.

70. The fatty acid-taxane conjugate composition of claim 14, wherein the amount of the at least one fatty acid-taxane conjugate is greater than about 100 mg/ml.

71. The fatty acid-taxane conjugate composition of claim 14, wherein the fatty acid is a C8-C26 unbranched, naturally occurring fatty acid.

72. The fatty acid-taxane conjugate composition of claim 71, wherein the fatty acid is docosohexaenoic acid.

73. The fatty acid-taxane conjugate composition of claim 17, wherein the concentration of Cremophor is between about 9.6% and about 49.7% (vol/vol).

18. A fatty acid-taxane conjugate composition, comprising at least one fatty acid-taxane conjugate and a surfactant, wherein the ratio of the weight of the at least one fatty acid-taxane conjugate and volume of the surfactant is at least about 50 mg/ml.

19. The fatty acid-taxane conjugate composition of claim 18, wherein the ratio of the weight of the at least one fatty acid-taxane conjugate and volume of the surfactant is at least about 100 mg/ml.

20. The fatty acid-taxane conjugate composition of claim 18, wherein the surfactant is a polyoxyethylated castor oil.

21. The fatty acid-taxane conjugate composition of claim 18, further comprising a solvent.

74. The fatty acid-taxane conjugate composition of claim 18, wherein the ratio of the weight of the at least one fatty acid-taxane conjugate and volume of the surfactant is at least about 60 mg/ml.

75. The fatty acid-taxane conjugate composition of claim 18, wherein the ratio of the weight of the at least one fatty acid-taxane conjugate and volume of the surfactant is at least about 70 mg/ml.

76. The fatty acid-taxane conjugate composition of claim 18, wherein the ratio of the weight of the at least one fatty acid-taxane conjugate and volume of the surfactant is at least about 80 mg/ml.

77. The fatty acid-taxane conjugate composition of claim 18, wherein the ratio of the weight of the at least one fatty acid-taxane conjugate and volume of the surfactant is at least about 90 mg/ml.

78. The fatty acid-taxane conjugate composition of claim 18, wherein the fatty acid is a C8-C26 unbranched, naturally occurring fatty acid.

79. The fatty acid-taxane conjugate composition of claim 78, wherein the fatty acid is docosahexaenoic acid.

80. The fatty acid-taxane conjugate composition of claim 18, wherein the taxane is paclitaxel or docetaxel.

81. The fatty acid-taxane conjugate composition of claim 21, wherein the solvent is ethanol.

82. The fatty acid-taxane conjugate composition of claim 81, wherein the solvent and the surfactant are present in a ratio of about 1:

1.

22. A fatty acid-taxane conjugate composition, comprising at least one fatty acid-taxane conjugate and a solvent, wherein the ratio of the weight of the at least one fatty acid-taxane conjugate and volume of the solvent is at least about 42 mg/ml.

23. The fatty acid-taxane conjugate composition of claim 22, wherein the ratio of the weight of the at least one fatty acid-taxane conjugate and volume of the solvent is at least about 80 mg/ml.

24. The fatty acid-taxane conjugate composition of claim 22, wherein the solvent is a polyoxyethylated castor oil.

25. The fatty acid-taxane conjugate composition of claim 22, further comprising a surfactant.

26. The fatty acid-taxane conjugate composition of claim 25, wherein the surfactant is a polyoxyethylated castor oil.

83. The fatty acid-taxane conjugate composition of claim 22, wherein the ratio of the weight of the at least one fatty acid-taxane conjugate and volume of the solvent is at least about 50 mg/ml.

84. The fatty acid-taxane conjugate composition of claim 22, wherein the ratio of the weight of the at least one fatty acid-taxane conjugate and volume of the solvent is at least about 60 mg/ml.

85. The fatty acid-taxane conjugate composition of claim 22, wherein the ratio of the weight of the at least one fatty acid-taxane conjugate and volume of the solvent is at least about 70 mg/ml.

86. The fatty acid-taxane conjugate composition of claim 22, wherein the ratio of the weight of the at least one fatty acid-taxane conjugate and volume of the solvent is at least about 100 mg/ml.

87. The fatty acid-taxane conjugate composition of claim 22, wherein the fatty acid is a C8-C26 unbranched, naturally occurring fatty acid.

88. The fatty acid-taxane conjugate composition of claim 87, wherein the fatty acid is docosahexaenoic acid.

89. The fatty acid-taxane conjugate composition of claim 22, wherein the taxane is paclitaxel or docetaxel.

90. The fatty acid-taxane conjugate composition of claim 26, wherein the solvent and the surfactant are present in a ratio of about 1:

1.

27. A fatty acid-taxane conjugate composition, comprising at least about 37 mg/ml of at least one fatty acid-taxane conjugate.

28. The fatty acid-taxane conjugate composition of claim 27, wherein the amount of the at least one fatty acid-taxane conjugate is least about 80 mg/ml.

91. The fatty acid-taxane conjugate composition of claim 27, wherein the amount of the at least one fatty acid-taxane conjugate is least about 40 mg/ml.

92. The fatty acid-taxane conjugate composition of claim 27, wherein the amount of the at least one fatty acid-taxane conjugate is least about 50 mg/ml.

93. The fatty acid-taxane conjugate composition of claim 27, wherein the amount of the at least one fatty acid-taxane conjugate is least about 60 mg/ml.

94. The fatty acid-taxane conjugate composition of claim 27, wherein the amount of the at least one fatty acid-taxane conjugate is least about 100 mg/ml.

95. The fatty acid-taxane conjugate composition of claim 27, wherein the fatty acid is a C8-C26 unbranched, naturally occurring fatty acid.

96. The fatty acid-taxane conjugate composition of claim 27, wherein the fatty acid is docosahexaenoic acid.

97. The fatty acid-taxane conjugate composition of claim 27, wherein the taxane is paclitaxel or docetaxel.

46. A method for increasing the therapeutic index of anticancer compounds in a subject, comprising:

conjugating a fatty acid to an anticancer compound to form a fatty acid-anticancer compound conjugate; and

administering the fatty acid-anticancer compound conjugate to the subject, whereby the therapeutic index of the anticancer compound is improved relative to non-conjugated formulations of the anticancer compound, and wherein the fatty acid-anticancer compound conjugate is in an amount which is at least about 30% on a molar basis greater than the maximum tolerated dose (MTD) in the subject for the non-conjugated anticancer compound.

47. The method of claim 46, wherein the anticancer compound is a taxane.

48. The method of claim 47, wherein the taxane is paclitaxel or docetaxel.

49. The method of claim 46, wherein the conjugate is not encapsulated in a liposome.

50. The method of claim 46, wherein the fatty acid is a C8-C26 unbranched, naturally occurring fatty acid.

51. The method of claim 50, wherein the fatty acid is docosohexaenoic acid.

52. The method of claim 46, wherein the subject is human.

53. A method for administering a fatty acid-taxane conjugate to a subject in need of such treatment, comprising infusing the conjugate in fewer than 3 hours.

54. The method of claim 53, wherein the conjugate is infused in 2 hours or less.